Developer docs
API playgroundTry for free, no card

Search company profiles

V-Bio Ventures

Full company profile

uuid0000qfe

Namestring
V-Bio Ventures
Legal namestring
V-Bio Ventures
Websiteurl
v-bio.ventures
Company typeenum
Private
Founded yearint
2015
Descriptiontext

V-Bio Ventures is an independent Belgian life science venture capital fund manager founded in 2015 and headquartered in Ghent, Belgium. The firm manages €186 million across two funds (Fund I at €76M final close in December 2016 and Fund II at €110M final close in March 2022) and invests in approximately 30 early- to mid-stage private companies focused on therapeutics — drug discovery and drug development — with a geographic remit spanning Europe and selective opportunities beyond. V-Bio sources deals primarily through a preferred, co-founder-level relationship with VIB (the Flanders Institute for Biotechnology) and additionally from European research institutes, academic spin-outs, entrepreneurial initiatives, and corporate spin-outs; the firm also co-creates startups from academic IP and takes board seats in portfolio companies.

The firm does not develop proprietary technology. Its "product" is capital plus hands-on company-building services: financing for clinical development and commercialization, strategic guidance, board participation, network access, and syndication with co-investors. Portfolio companies span modalities including GPCR antibody therapeutics (Confo), Treg cell therapies (Dualyx), molecular glues (Orionis), antibody-drug conjugates (ATB Therapeutics, Avidicure), fibrosis (Agomab), radiopharmaceuticals (Precirix), cardiovascular (Corteria), neuromuscular disease (Augustine), obesity (Tanai), vaccines (AstriVax), and agricultural biologicals (Protealis, RootWave, Aphea.Bio). The team comprises three Managing Partners (Christina Takke, Willem Broekaert, Shelley Margetson), two Partners (Ward Capoen, Katja Rosenkranz), one Venture Partner (Mathias Falcenberg, joined February 2025), a Finance Manager (Martin Solleveld), and an Advisor (Tom Schwarz), supported by institutional LP capital from EIF, InnovFin/EFSI/EU, Korys, ARKimedes, KU Leuven, UGent, Gimv, BNP Paribas Fortis Private Equity, and FPIM/SFPI.

Revenue mechanics follow the standard VC model: recurring management fees on committed capital (~1.5–2.5% of AUM annually) plus lumpy carried interest on successful exits. Notable realized liquidity events include the Syndesi Therapeutics acquisition by AbbVie (March 2022) and the Confo Therapeutics worldwide licensing agreement with Lilly for CFTX-1554 ($40M upfront, up to $590M in milestones, March 2023). The Orionis–Genentech collaborations ($105M upfront in the second deal, May 2025) and Augustine Therapeutics' oversubscribed €78M Series A (March 2025) further validate portfolio momentum.

Short descriptiontext

V-Bio Ventures is a Belgian life science venture capital fund manager founded in 2015 that manages €186M across two funds, investing in early- to mid-stage therapeutics companies across Europe with a preferred relationship with VIB.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersGent, Belgium
HQ citystring
Gent
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life science venture capital, early-stage biotech investment, therapeutics funding, startup co-creation, European biotech fund
Industry2 codes
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
SECONDARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
NAICS code1 code
  • Other Investment Pools and Funds5259
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital / Life Sciences Investment Management
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Management Fees and Carried Interest
TypeSubscription Recurring
Description

V-Bio generates revenue through management fees on funds under management and carried interest (performance fees) from successful portfolio company exits. As a VC fund, they co-create and invest in early-stage life science companies with the expectation of returns through M&A, licensing deals, or IPOs.

v-bio.ventures
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

V-Bio Ventures is a life science venture capital fund that co-creates startups and invests in early- to mid-stage companies with high growth potential. The firm manages €186 million across two funds focused on therapeutics (drug discovery and drug development), targeting private companies with differentiated technology addressing unmet needs. V-Bio contributes more than capital by providing strategic guidance, mentorship, network access, and active board participation to portfolio companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Successful exits including Syndesi Therapeutics acquired by AbbVie
+1 more record
Product overview1 text field

V-Bio Ventures operates as a dual-fund life science venture capital platform managing €186 million across two funds (Fund I at €76M and Fund II at €110M). The firm offers three integrated offerings: its core investment funds targeting early/mid-stage therapeutics companies, startup co-creation services that leverage the VIB partnership to build companies from scientific discoveries, and access to a curated portfolio of approximately 15 portfolio companies. The fund focuses primarily on European biotech with a preferred relationship with Belgium-based VIB research institute, while also sourcing deals from other top research organizations throughout Europe.

Product and service3 records
1V-Bio Ventures Fund I
CategoryVenture Capital Fund
Description

V-Bio Ventures' first venture capital fund focused on early-stage life science investments, which achieved final closing at over €76 million. The fund targeted private companies with differentiated technology addressing unmet needs in therapeutics and adjacent life science sectors.

2V-Bio Ventures Fund II
CategoryVenture Capital Fund
Description

V-Bio Ventures' second venture capital fund, raised to €110 million, continuing the firm's early/mid-stage life science investment strategy across Europe with a thematic focus on therapeutics.

3Startup Co-Creation Services
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

V-Bio Ventures has a preferred, co-founder relationship with VIB, one of the world's premier life science research institutes. Part of companies V-Bio co-creates are built on VIB-derived innovations. VIB is a co-founder and minor investor in V-Bio. The fund provides early access to VIB's pipeline of innovations and works closely with VIB's Technology Transfer Office.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Forbion is a leading European life sciences VC firm headquartered in the Netherlands, actively investing in early to late-stage biotech and therapeutic companies. Two V-Bio Managing Partners previously worked at Forbion (Christina Takke as Partner; Mathias Falcenberg as investment professional), and Forbion is a direct comparable in stage, sector focus, and European biotech deal sourcing.

TypeDirect peer
Description

LSP is a Netherlands-based European life sciences and healthcare VC firm investing across early and growth stages in therapeutics, medical devices, and digital health. V-Bio advisor Tom Schwarz co-founded LSP, making it a direct comparable in pan-European life sciences VC.

TypeDirect peer
Description

BGV is a Netherlands-based early-stage life sciences VC firm focused on European biotech startups, often co-investing with V-Bio (e.g., Tanai Therapeutics with Novo Nordisk). Highly comparable in stage, sector focus, and European biotech thesis.

TypeDirect peer
Description

Thuja Capital is a Dutch early-stage life sciences and healthcare VC fund investing in therapeutics and medtech. V-Bio's Finance Manager Martin Solleveld has prior Thuja Capital experience; comparable stage and European life sciences focus.

5EQT Life Sciences (formerly LSP Investments)
TypeBroad incumbent
Description

EQT Life Sciences is a large-scale, multi-stage life sciences investor operating venture and growth funds across Europe and the US with €2bn+ AUM. Functions as a broad incumbent comparable in sector and stage, though at much larger scale than V-Bio.

TypeDirect peer
Description

Gilde Healthcare is a Netherlands-based specialized healthcare investor covering therapeutics, medical devices, and healthcare services across Europe. Direct comparable in European early-stage healthcare VC, often co-investing in similar rounds.

TypeDirect peer
Description

Kurma Partners is a France-based early-stage healthcare VC firm investing in therapeutics and digital health. Direct comparable in European life sciences VC stage, sector, and deal syndication.

TypeBroad incumbent
Description

HealthCap is a Nordic/European venture and growth investor focused on life sciences with over €1bn raised across funds. A comparable European specialist, though typically investing at larger check sizes than V-Bio.

TypeBroad incumbent
Description

Andera Partners operates a dedicated life sciences practice within a broader European private equity platform, investing in therapeutics and medtech from early to growth stages. Comparable as a European life sciences investor.

TypeBroad incumbent
Description

Sofinnova Partners is a leading European life sciences VC firm with multi-fund platforms spanning biotech, medtech, and industrial bio. Comparable in European biotech VC focus though at significantly larger AUM scale than V-Bio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment43 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

V-Bio Ventures

Venture Capital / Life Sciences Investment Managementv-bio.ventures

V-Bio Ventures is a Belgian life science venture capital fund manager founded in 2015 that manages €186M across two funds, investing in early- to mid-stage therapeutics companies across Europe with a preferred relationship with VIB.

What V-Bio Ventures does

V-Bio Ventures is an independent Belgian life science venture capital fund manager founded in 2015 and headquartered in Ghent, Belgium. The firm manages €186 million across two funds (Fund I at €76M final close in December 2016 and Fund II at €110M final close in March 2022) and invests in approximately 30 early- to mid-stage private companies focused on therapeutics — drug discovery and drug development — with a geographic remit spanning Europe and selective opportunities beyond. V-Bio sources deals primarily through a preferred, co-founder-level relationship with VIB (the Flanders Institute for Biotechnology) and additionally from European research institutes, academic spin-outs, entrepreneurial initiatives, and corporate spin-outs; the firm also co-creates startups from academic IP and takes board seats in portfolio companies.

The firm does not develop proprietary technology. Its "product" is capital plus hands-on company-building services: financing for clinical development and commercialization, strategic guidance, board participation, network access, and syndication with co-investors. Portfolio companies span modalities including GPCR antibody therapeutics (Confo), Treg cell therapies (Dualyx), molecular glues (Orionis), antibody-drug conjugates (ATB Therapeutics, Avidicure), fibrosis (Agomab), radiopharmaceuticals (Precirix), cardiovascular (Corteria), neuromuscular disease (Augustine), obesity (Tanai), vaccines (AstriVax), and agricultural biologicals (Protealis, RootWave, Aphea.Bio). The team comprises three Managing Partners (Christina Takke, Willem Broekaert, Shelley Margetson), two Partners (Ward Capoen, Katja Rosenkranz), one Venture Partner (Mathias Falcenberg, joined February 2025), a Finance Manager (Martin Solleveld), and an Advisor (Tom Schwarz), supported by institutional LP capital from EIF, InnovFin/EFSI/EU, Korys, ARKimedes, KU Leuven, UGent, Gimv, BNP Paribas Fortis Private Equity, and FPIM/SFPI.

Revenue mechanics follow the standard VC model: recurring management fees on committed capital (~1.5–2.5% of AUM annually) plus lumpy carried interest on successful exits. Notable realized liquidity events include the Syndesi Therapeutics acquisition by AbbVie (March 2022) and the Confo Therapeutics worldwide licensing agreement with Lilly for CFTX-1554 ($40M upfront, up to $590M in milestones, March 2023). The Orionis–Genentech collaborations ($105M upfront in the second deal, May 2025) and Augustine Therapeutics' oversubscribed €78M Series A (March 2025) further validate portfolio momentum.

V-Bio Ventures firmographics

Firmographics
Name
V-Bio Ventures
Legal name
V-Bio Ventures
Website
https://v-bio.ventures
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
V-Bio Ventures is a Belgian life science venture capital fund manager founded in 2015 that manages €186M across two funds, investing in early- to mid-stage therapeutics companies across Europe with a preferred relationship with VIB.
Ownership category
akta.pro rank

V-Bio Ventures industry classification

Industry
Product category
Venture Capital / Life Sciences Investment Management
NAICS
Other Investment Pools and Funds (5259)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
SECONDARYFSANAAAB
Early-Stage Venture Capital (Series A/B)

Keywords

  • Life science venture capital
  • Early-stage biotech investment
  • Therapeutics funding
  • Startup co-creation
  • European biotech fund

Where V-Bio Ventures is headquartered

Location

Headquarters

HQ city
Gent
HQ country
Belgium
HQ region
Europe

Offices1 record

Markets served

V-Bio Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Management Fees and Carried Interest: V-Bio generates revenue through management fees on funds under management and carried interest (performance fees) from successful portfolio company exits. As a VC fund, they co-create and invest in early-stage life science companies with the expectation of returns through M&A, licensing deals, or IPOs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

V-Bio Ventures product offering

Product offering

Core offering

V-Bio Ventures is a life science venture capital fund that co-creates startups and invests in early- to mid-stage companies with high growth potential. The firm manages €186 million across two funds focused on therapeutics (drug discovery and drug development), targeting private companies with differentiated technology addressing unmet needs. V-Bio contributes more than capital by providing strategic guidance, mentorship, network access, and active board participation to portfolio companies.

Product overview

V-Bio Ventures operates as a dual-fund life science venture capital platform managing €186 million across two funds (Fund I at €76M and Fund II at €110M). The firm offers three integrated offerings: its core investment funds targeting early/mid-stage therapeutics companies, startup co-creation services that leverage the VIB partnership to build companies from scientific discoveries, and access to a curated portfolio of approximately 15 portfolio companies. The fund focuses primarily on European biotech with a preferred relationship with Belgium-based VIB research institute, while also sourcing deals from other top research organizations throughout Europe.

Differentiator

Problem solved

Functional benefit

Products and services

  • V-Bio Ventures Fund I V-Bio Ventures' first venture capital fund focused on early-stage life science investments, which achieved final closing at over €76 million. The fund targeted private companies with differentiated technology addressing unmet needs in therapeutics and adjacent life science sectors.
  • V-Bio Ventures Fund II V-Bio Ventures' second venture capital fund, raised to €110 million, continuing the firm's early/mid-stage life science investment strategy across Europe with a thematic focus on therapeutics.
  • Startup Co-Creation Services

Quantifiable outcome

  • Successful exits including Syndesi Therapeutics acquired by AbbVie
  • +1 more outcomes

Companies that use V-Bio Ventures

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

V-Bio Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

V-Bio Ventures partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • VIB (Flanders Institute for Biotechnology)coreStrategic or Co-development Partner · 1 January 2015V-Bio Ventures has a preferred, co-founder relationship with VIB, one of the world's premier life science research institutes. Part of companies V-Bio co-creates are built on VIB-derived innovations. VIB is a co-founder and minor investor in V-Bio. The fund provides early access to VIB's pipeline of innovations and works closely with VIB's Technology Transfer Office.

Scale indicators3 records

Recent moves9 records

Expansion highlights5 records

V-Bio Ventures competitors and assessment

Company assessment

Direct peers

  • Forbion: Forbion is a leading European life sciences VC firm headquartered in the Netherlands, actively investing in early to late-stage biotech and therapeutic companies. Two V-Bio Managing Partners previously worked at Forbion (Christina Takke as Partner; Mathias Falcenberg as investment professional), and Forbion is a direct comparable in stage, sector focus, and European biotech deal sourcing.
  • LSP (Life Sciences Partners): LSP is a Netherlands-based European life sciences and healthcare VC firm investing across early and growth stages in therapeutics, medical devices, and digital health. V-Bio advisor Tom Schwarz co-founded LSP, making it a direct comparable in pan-European life sciences VC.
  • BioGeneration Ventures (BGV): BGV is a Netherlands-based early-stage life sciences VC firm focused on European biotech startups, often co-investing with V-Bio (e.g., Tanai Therapeutics with Novo Nordisk). Highly comparable in stage, sector focus, and European biotech thesis.
  • Thuja Capital Healthcare Fund: Thuja Capital is a Dutch early-stage life sciences and healthcare VC fund investing in therapeutics and medtech. V-Bio's Finance Manager Martin Solleveld has prior Thuja Capital experience; comparable stage and European life sciences focus.
  • Gilde Healthcare: Gilde Healthcare is a Netherlands-based specialized healthcare investor covering therapeutics, medical devices, and healthcare services across Europe. Direct comparable in European early-stage healthcare VC, often co-investing in similar rounds.
  • Kurma Partners: Kurma Partners is a France-based early-stage healthcare VC firm investing in therapeutics and digital health. Direct comparable in European life sciences VC stage, sector, and deal syndication.

Broad incumbents

  • EQT Life Sciences (formerly LSP Investments): EQT Life Sciences is a large-scale, multi-stage life sciences investor operating venture and growth funds across Europe and the US with €2bn+ AUM. Functions as a broad incumbent comparable in sector and stage, though at much larger scale than V-Bio.
  • HealthCap: HealthCap is a Nordic/European venture and growth investor focused on life sciences with over €1bn raised across funds. A comparable European specialist, though typically investing at larger check sizes than V-Bio.
  • Andera Partners (Life Sciences): Andera Partners operates a dedicated life sciences practice within a broader European private equity platform, investing in therapeutics and medtech from early to growth stages. Comparable as a European life sciences investor.
  • Sofinnova Partners: Sofinnova Partners is a leading European life sciences VC firm with multi-fund platforms spanning biotech, medtech, and industrial bio. Comparable in European biotech VC focus though at significantly larger AUM scale than V-Bio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

V-Bio Ventures social profiles

Digital presence

V-Bio Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

V-Bio Ventures leadership team

Management profile

Number of profiles

Profiles9 records

V-Bio Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

V-Bio Ventures M&A and investment

M&A and investment

M&A

Investments43 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about V-Bio Ventures

What does V-Bio Ventures do?

V-Bio Ventures is a life science venture capital fund that co-creates startups and invests in early- to mid-stage companies with high growth potential. The firm manages €186 million across two funds focused on therapeutics (drug discovery and drug development), targeting private companies with differentiated technology addressing unmet needs. V-Bio contributes more than capital by providing strategic guidance, mentorship, network access, and active board participation to portfolio companies.

Is V-Bio Ventures a public or private company?

V-Bio Ventures is a private company. It is classified as management employee owned and is currently operating.

When was V-Bio Ventures founded?

V-Bio Ventures was founded in 2015. It employs 1 to 10 people.

Where is V-Bio Ventures based?

V-Bio Ventures is headquartered in Gent, Belgium, in the Europe region.

How does V-Bio Ventures make money?

One revenue line is on record: management Fees and Carried Interest.

Who are V-Bio Ventures's main competitors?

Direct peers on record are Forbion, LSP (Life Sciences Partners), BioGeneration Ventures (BGV), Thuja Capital Healthcare Fund, Gilde Healthcare and Kurma Partners. Broad incumbents are EQT Life Sciences (formerly LSP Investments), HealthCap, Andera Partners (Life Sciences) and Sofinnova Partners.

Does V-Bio Ventures have an API?

No public API is recorded for V-Bio Ventures.

What industry is V-Bio Ventures in?

V-Bio Ventures's product category is Venture Capital / Life Sciences Investment Management. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists), with a secondary code of FSANAAAB, Early-Stage Venture Capital (Series A/B). Its NAICS code is 5259 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceAugustine Therapeutics to Present Late-Breaking Poster at the American Diabetes Association’s 86th Scientific SessionsAugustine Therapeutics will present a late-breaking poster at the ADA's 2026 Scientific Sessions in New Orleans, June 5-8, 2026. The poster will feature in vivo efficacy results for an HDAC6 inhibitor in a preclinical mouse model of heart failure with preserved ejection fraction. The company's CSO highlighted the need for novel HFpEF therapies.PharmiWeb.comV-Bio Ventures leads €20 million Series A financing of Precision oncology company Flindr Therapeutics to advance first-in-class small molecule inhibitorsFlindr Therapeutics secured a €20 million Series A financing led by V-Bio Ventures to advance its pipeline of first-in-class small molecule inhibitors for cancer treatment. The investment round included participation from Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, and other existing investors. Flindr intends to use the capital to progress its lead RNF31 inhibitor program toward an Investigational New Drug (IND) application.BiovoxV-Bio Ventures leads €20 million Series A financing of Precision oncology company Flindr Therapeutics to advance first-in-class small molecule inhibitorsV-Bio Ventures led a €20 million Series A financing for precision oncology company Flindr Therapeutics to advance its pipeline of small molecule inhibitors. The investment round included participation from Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital, and existing investors Oncode Oncology Bridge Fund, Swanbridge, and BOM. Flindr intends to use the funds to progress its lead RNF31 inhibitor program toward an Investigational New Drug application and develop additional therapies.BiovoxV-Bio Ventures portfolio company Protealis secures EUR 22 million in oversubscribed B round funding to propel sustainable plant protein seed solutionsProtealis, a Belgian seed solutions company focused on sustainable plant proteins, secured EUR 22 million in an oversubscribed Series B funding round led by its existing investor base. The capital will be used to accelerate commercial development and expand operations in key European markets while enhancing its AI-driven crop performance prediction technologies. This funding marks a significant milestone for the company as it continues to develop proprietary soy and legume varieties tailored for colder European climates.BiovoxV-Bio Ventures-funded Tanai Therapeutics develops first-in-class therapeutics for obesityV-Bio Ventures-backed Tanai Therapeutics has launched as a spin-off from the VIB-UGent Center for Inflammation Research to develop first-in-class therapeutics for obesity. The company secured seed funding from V-Bio Ventures, Qbic III, and VIB to pursue a novel, orally administered drug target aimed at promoting fat loss while preserving muscle mass. This initiative addresses a significant unmet medical need in the global obesity market, which is currently dominated by incretin mimetics.FinSMEsV-Bio Ventures Closes Second Fund, at EUR 110MV-Bio Ventures closed its second fund, V-Bio Fund 2, at EUR 110m, with nearly all first-fund LPs and new investors. The firm now manages over EUR 185m and expanded its team to nine professionals, including Shelley Margetson as Managing Partner.BiovoxV-Bio Ventures participates in the EUR 12 million seed round of heart failure biotech Corteria PharmaceuticalsCorteria Pharmaceuticals, a French heart failure biotech founded in 2021, announced on 9 December 2021 that it completed a EUR 12 million seed round led by Kurma Partners, with V-Bio Ventures, Omnes Capital and InVivo Capital participating. The funding will develop programs in-licensed from Sanofi, and four investors joined the board.GlobalaginvestingV-Bio Ventures, Rabo Food & Agri Innovation Fund Lead EUR6.5 Million Series A for Electric Weed Killer Startup RootWaveV-Bio Ventures and Rabo Food & Agri Innovation Fund led a EUR6.5 million Series A for RootWave, a UK-based startup developing an electric weed-killing technology. The funds will integrate the technology into automated weeders and advance commercialization. RootWave is partnering with Small Robot Company for an automated weed robot expected in field trials this year.FinSMEsCamel-IDS Secures €37M in Series A FundingCamel-IDS, a Brussels-based cancer-targeted radiopharmaceutical developer, raised €37M in Series A funding led by V-Bio Ventures and Gimv. The company will use the funds for a phase Ib/II trial of its lead program CAM-H2 and further development of preclinical programs.GlobeNewswirePrecision Ocular Ltd: Completion of £15.5 Million Series A FinancingPrecision Ocular completed an oversubscribed £15.5 million Series A financing round, with V-Bio Ventures joining the investment syndicate. The funds will develop treatments for retinal diseases like age-related macular degeneration and diabetic macular oedema, and next-generation ocular drug delivery systems.